| Document |
Document Title |
|
WO/2023/165905A1 |
A composition for use in a method of treating, or methods of treating, atopic dermatitis, wherein the composition is topically applied on the skin at least 2 times a day, wherein the composition has a pH in the range of 2.7 to 5.0 and in...
|
|
WO/2023/160405A1 |
Provided is a compound NMNH disodium salt, and the present invention in particular relates to a polymorph of a reduced β-nicotinamide mononucleotide disodium salt, and a preparation method therefor and the use thereof as a pharmaceutica...
|
|
WO/2023/163539A1 |
The present invention relates to a use of a novel pomalidomide derivative which is for treating brain diseases, and exhibits improved pharmacological effects as compared to pomalidomide. The novel pomalidomide derivative according to the...
|
|
WO/2023/161264A1 |
The present disclosure relates to the use of a combination of a known neuronal exocytosis inhibitor, and a known TRPV1 modulator in the treatment and/or prevention of diseases or conditions that courses through an excessive neural stimul...
|
|
WO/2023/160727A1 |
A use of an indazole compound represented by formula (I), a stereoisomer, a racemate, a tautomer, an isotopic marker, and a prodrug thereof, or a pharmaceutically acceptable salt thereof in the preparation of a drug for treating and/or p...
|
|
WO/2023/161938A1 |
A pharmaceutical composition is described herein, which comprises a therapeutically active agent, an absorption enhancer, and a polymer comprising a plurality of alkaline groups. The therapeutically active agent is a peptide which is a k...
|
|
WO/2023/162363A1 |
The purpose of the present invention is to provide a formulation which is for producing an oil-in-water emulsion composition that has zinc chloride as an active component and which provides excellent separation inhibiting properties and/...
|
|
WO/2023/160458A1 |
The present invention relates to a Chinese herbal medicine active substance @ vesicle complex having hair care and growth effects, and a preparation method therefor and the use thereof. The complex comprises a Chinese herbal medicine act...
|
|
WO/2023/161887A1 |
The present disclosure relates to methods for treating and/or preventing Hidradenitis Suppurativa in a subject having such disease or condition comprising administering a therapeutically effective dose of LOU064. Also disclosed are medic...
|
|
WO/2023/161505A1 |
The present invention relates to compounds of formula (I), which are modulators of sortilin activity, pharmaceutical compositions comprising these compounds and the use of these compounds in the treatment or prevention of medical conditi...
|
|
WO/2023/163538A1 |
The present invention relates to: a novel pomalidomide derivative exhibiting effects better than those of pomalidomide; a preparation method therefor; and use thereof. The novel pomalidomide derivative according to the present invention ...
|
|
WO/2023/164024A1 |
The present disclosure encompasses solid state forms of Gusacitinib, in embodiments crystalline polymorphs of Gusacitinib, processes for preparation thereof, and pharmaceutical compositions thereof.
|
|
WO/2023/163555A1 |
The present invention relates to a novel hydantoin derivative and a composition comprising same for preventing or treating NADPH oxidase (NOX)-related diseases. The present invention can be used for the treatment of NADPH oxidase (NOX)-r...
|
|
WO/2023/161179A1 |
The invention relates to a liposomal composition comprising biosurfactants and the use of the liposomal composition for encapsulation of at least one cosmetic, pharmaceutical and/or nutraceutical active ingredient.
|
|
WO/2023/164241A1 |
The invention relates to a method of enriching Muse cells and obtaining the exosomes, microvesicles, or the secretome therefrom, in several embodiments, the exosomes, microvesicles, secretome or Muse cells may be used in therapeutic meth...
|
|
WO/2023/161050A1 |
In order to provide new active agents for treating skin aging in subjects without undesired side effects the present invention discloses active agents activating, enhancing, or positively modulating the cellular response of the transient...
|
|
WO/2023/163465A1 |
The present invention provides a composition for hair loss prevention or hair growth promotion, the composition comprising a Philadelphus schrenckii flower extract as an active ingredient.
|
|
WO/2023/161670A1 |
The present invention relates to pharmaceutical compositions and methods for obtaining said pharmaceutical compositions comprising a conditioned culture medium of human mesenchymal stem cells and/or a combination of trophic factors expre...
|
|
WO/2023/164272A1 |
Provided herein are compositions comprising an active ingredient mixture comprising silicon and biotin, compositions comprising an active ingredient mixture comprising inositol-stabilized arginine silicate complex (ASI) and magnesium bio...
|
|
WO/2023/161326A1 |
The present invention relates to improved methods for the use of the compound according to Formula (I) in the treatment of inflammatory diseases, and/or diseases associated with hypersecretion of INFα and/or interferons ("interferonopat...
|
|
WO/2023/155144A1 |
The present disclosure provides methods for regulating angiogenesis, also provides a method for regulating angiogenesis and/or an angiogenesis related biological process, comprising regulating the formation and/or function of a migrasome...
|
|
WO/2023/155158A1 |
A use of a composition in preparation of a medicament for promoting wound healing in diabetes is provided, wherein the composition comprises an effective amount of mangosteen fruit shell extract.
|
|
WO/2023/156745A1 |
The present invention relates to a cosmetic or dermatological composition comprising a myrtle extract and a Tripterygium wilfordii extract, in particular with at least one cosmetically acceptable or dermatologically acceptable excipient,...
|
|
WO/2023/158281A1 |
The present invention relates to a metal thiooctoyl hyaluronate complex and a composition comprising same, the complex consisting of alpha-lipoic acid, metal, and hyaluronic acid. The metal thiooctoyl hyaluronate complex of the present i...
|
|
WO/2023/155837A1 |
PHARMACEUTICAL COMPOSITION HAVING ANALGESIC AND/OR ANTIPRURITIC FUNCTIONS AND USE THEREOF The composition contains a Nav1.7 inhibitor and a Nav1.8 inhibitor, and the weight ratio of the Nav1.7 inhibitor to the Nav1.8 inhibitor is 1:(0.00...
|
|
WO/2023/158242A1 |
Provided are a polypeptide having hair loss treating or hair growth promoting activity and use thereof.
|
|
WO/2023/155880A1 |
A method for regulating membrane repair and/or a membrane repair related biological process is provided, comprising regulating the amount and/or function of TSPAN4, which can help cells mitigate damage caused by laser, detergent, pyropto...
|
|
WO/2023/156588A1 |
The present invention relates to the cosmetic use of at least one dirhamnolipid of general formula (I): and also the salts thereof, solvates thereof and optical isomers thereof, for reducing and/or inhibiting the development of the colou...
|
|
WO/2023/156864A1 |
Provided is an inhibitor of AXL, Mer, and/or c-Met of Formula (I) or a pharmaceutically acceptable salt thereof: Formula (I), in which R1, R2, R3, G, and Q are described herein. Further provided is a method of treating or preventing an A...
|
|
WO/2023/158051A1 |
The present invention relates to: a peptide exhibiting an anti-inflammatory function; a fused compound comprising same; and drugs, cosmetics, foods, medical devices, etc. comprising same. The present inventors discovered that a peptide o...
|
|
WO/2023/155756A1 |
Disclosed in the present invention is the use of a lipoic acid nanoparticle in the preparation of a drug for treating diseases related to oxidative stress, which belongs to the technical field of biomedicine. The drug for treating diseas...
|
|
WO/2023/158164A1 |
The present invention relates to a composition for promoting collagen production, comprising an amidated amino acid and, more specifically, to a composition which, by promoting collagen production in various cells such as fibroblasts, ha...
|
|
WO/2023/158286A1 |
The present invention pertains to a calsequestrin-based metal ion reactive particle and uses thereof. More specifically, the present invention pertains to: a calsequestrin-based metal ion reactive particle prepared by binding a physiolog...
|
|
WO/2023/155879A1 |
Provided are methods and compositions for regulating an immune cell relating functions, by regulating the formation and/or function of a migrasome generated by another immune cell.
|
|
WO/2023/159123A1 |
The current disclosure provides compositions and methods for treating and/or debriding damaged or dying tissue resulting from a range of injuries and conditions without requiring surgical personnel or facilities. The compositions can be ...
|
|
WO/2023/158092A1 |
Provided are a pharmaceutical composition for hemostasis in the gastrointestinal tract and a pharmaceutical composition for wound healing in the gastrointestinal tract. The pharmaceutical compositions, according to one embodiment, may co...
|
|
WO/2023/154953A1 |
The present disclosure provides methods of treating and preventing autoimmune disorders (e.g., multiple sclerosis (MS)), said methods comprising administering to a subject (e.g., a human) in need thereof a therapeutically effective amoun...
|
|
WO/2023/152727A1 |
Dermatological composition comprising: - water present in a concentration by weight, evaluated with respect to the total weight of the composition, greater than 30%; - at least one hydrolyzed extract of silk proteins present in a concent...
|
|
WO/2023/153861A1 |
The present invention relates to a pharmaceutical composition comprising curcumin and ginsenoside, and a formulation comprising same. Using curcumin and ginsenoids according to the present invention in combination with butyric acid and s...
|
|
WO/2023/153776A1 |
The composition containing deglycosylated recombinant keratin as an active ingredient has hair growth promotion and hair regeneration effects superior to those of glycosylated human hair keratin, and thus can be used for preventing and t...
|
|
WO/2023/152241A1 |
The invention relates to an agent from the group of anion exchangers, preferably colestyramine, for the care and prophylaxis of wounds and injuries, in particular in the presence of local bacterial infections or critical colonizations, w...
|
|
WO/2023/154014A1 |
The usage of NMDAR antagonists provides compositions and methods for treatment for the malfunctioning of the protein homeostasis network and interferes with crucial signaling pathways and is often associated with multiple human diseases....
|
|
WO/2023/154479A1 |
The present disclosure relates to a formulations and methods for transdermal delivery of a medicament through the skin of a subject. In aspects, the formulation comprises a therapeutically effective amount of a medicament and a penetrant...
|
|
WO/2023/151898A1 |
The invention relates to compounds of general formula (I).
|
|
WO/2023/151897A1 |
The invention relates to compounds of general formula (I).
|
|
WO/2023/152748A1 |
The present invention relates to skin care preparations comprising callus-derived pluripotent cells of a plant of the genus Cannabis, including Cannabis saliva I.,, and Cannabis indica, compositions comprising same and use thereof for pr...
|
|
WO/2023/153479A1 |
A cell population which contains 75% or more of CD11b positive, F4/80 positive, CD180 positive and CD9 positive macrophages derived from a tissue selected from the group consisting of placenta, umbilical cord and amnion, and which contai...
|
|
WO/2023/152656A2 |
Formulations containing biologically-produced, high-purity R-mevalonolactone are provided for modulating the expression of genes and metabolism related to epidermal turnover, hyaluronic acid synthesis, barrier function, anti-aging elasti...
|
|
WO/2023/150376A1 |
Provided herein are methods and compositions related to Prevotella histicola bacteria for the reduction of IL-23, LL-12b, and IL-17 levels in a subject.
|
|
WO/2023/149227A1 |
[Problem] To provide a skin care composition that effectively inhibits elastase activity. [Solution] A skin care composition comprising (A) a cyclic carboxamide derivative having a specific structure or a salt of the derivative, and (B) ...
|
